Multicenter review of liver transplant for hepatitis B‐related liver disease: disparities in gender and ethnicity

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Transplantation

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ctr.12224PMID 24033475
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• What Is the Outcome of

  2015cited by this paper
• Posttransplantation prophylaxis with primary high‐dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add‐on

  2011cited by this paper
• Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy

  2011cited by this paper
• Hepatitis C virus–infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men

  2011cited by this paper
• Posttransplantation Hepatitis B Prophylaxis with Combination Oral Nucleoside and Nucleotide Analog Therapy

  2011cited by this paper
• Clinical management of hepatitis B virus infection correlated with liver transplantation.

  2010cited by this paper
• The impact of donor race on recurrent hepatitis C after liver transplantation.

  2010cited by this paper
• Virologic and Clinical Outcomes of Hepatitis B Virus Infection in HIV‐HBV Coinfected Transplant Recipients

  2010cited by this paper
• Impact of Virologic Breakthrough and HBIG Regimen on Hepatitis B Recurrence After Liver Transplantation

  2010cited by this paper
• Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.

  2009cited by this paper
• The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C

  2009cited by this paper
• Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B.

  2007cited by this paper
• Low risk of hepatitis B virus recurrence after withdrawal of long‐term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy

  2007cited by this paper
• Retransplantation for hepatitis C: Results of a U.S. multicenter retransplant study

  2007cited by this paper
• Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis

  2006cited by this paper
• Liver (Including Intrahepatic Bile Ducts)

  2006cited by this paper
• Resection and Liver Transplantation for Hepatocellular Carcinoma

  2005cited by this paper
• Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort.

  2005cited by this paper
• Differential Effects of Donor Age in Liver Transplant Recipients Infected With Hepatitis B, Hepatitis C and Without Viral Hepatitis

  2005cited by this paper
• Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C

  2005cited by this paper
• Liver transplantation for hepatitis B in the United States.

  2005cited by this paper
• Twenty-year experience with liver transplantation for hepatocellular carcinoma.

  2005cited by this paper
• Predictors of Long-Term Survival After Liver Transplantation for Hepatocellular Carcinoma

  2005cited by this paper
• Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B

  2004cited by this paper
• Lamivudine for patients with chronic hepatitis B and advanced liver disease.

  2004cited by this paper
• Outcome of liver transplantation for hepatitis B in the United States

  2004cited by this paper
• Evolving strategies to prevent HBV recurrence

  2004cited by this paper
• Natural history of hepatitis B and outcomes after liver transplantation.

  2003cited by this paper
• Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost‐effective in patients receiving long‐term prophylaxis to prevent hepatitis B recurrence after liver transplantation

  2003cited by this paper
• New Era of Liver Transplantation for Hepatitis B: A 17-Year Single-Center Experience

  2002cited by this paper
• Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C

  2002cited by this paper
• Hepatitis B e antigen and the risk of hepatocellular carcinoma.

  2002cited by this paper
• Liver transplantation in association with hepatocellular carcinoma: An update of the international tumor registry

  2002cited by this paper
• Combination low‐dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B

  2000cited by this paper
• Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation

  2000cited by this paper
• An efficacy and cost‐effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy

  2000cited by this paper
• Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin

  1996cited by this paper
• Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients

  1995cited by this paper

• Disparities in Health Care in Patients With Chronic Liver Disease.

  2025cites this paper
• Health disparities in chronic liver disease

  2022cites this paper
• Gender Differences in Liver Transplantation Outcomes in Polycystic Liver Disease

  2021cites this paper
• Risk factors for early viral infections after liver transplantation

  2018cites this paper
• Ethnic Disparities in Chronic Hepatitis B Infection: African Americans and Hispanic Americans

  2017cites this paper
• Organ Transplantation in HBV-Infected Patients

  2016cites this paper
• 2013 Publications of the Baylor Health Care System Medical and Scientific Staff

  2014cites this paper
• (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes.

  2014cites this paper
• Female gender in the setting of liver transplantation.

  2014cites this paper
• Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues

  2013cites this paper
• World Journal of Hepatology

  year unknowncites this paper